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Abstract 
During pregnancy uterine smooth muscle 
(USM) co-ordinately adapts its contractile 
phenotype in order to accommodate the 
developing foetus and then prepare for 
delivery. Herein we show that SMTNL1 plays 
a major role in pregnancy to promote 
adaptive responses in USM and that this 
process is specifically mediated through 
interactions of SMTNL1 with the steroid 
hormone receptor PR-B. In vitro and in vivo 
SMTNL1 selectively binds PR and not other 
steroid hormone receptors. The physiological 
relationship between the two proteins was 
also established in global gene expression and 
transcriptional reporter studies in pregnant 
smtnl1-/- mice and by RNA interference in 
progesterone sensitive cell lines. We show that 
the contraction-associated and progestin-
sensitive genes (oxytocin receptor, connexin 
43 and cyclooxygenase-2) and prolactins are 
down-regulated in pregnant smtnl1-/- mice. 
We suggest SMTNL1 is a bifunctional co-
regulator of PR-B signaling and thus provides 
a molecular mechanism whereby PR-B is 
targeted to alter gene expression patterns 
within USM cells to co-ordinately promote 
alterations in USM function during 
pregnancy.  
 
Introduction 
Uterine smooth muscle cells (USM) show a high 
degree of plasticity and are capable of 
transforming their phenotype in response to a 
variety of physiological stresses such as 
pregnancy. In pregnancy, USM cells go through 
a number of extensive phenotypic changes 
characterized by the expression of a distinct set 
of proteins (1,2). In early pregnancy, USM cells 
proliferate rapidly under the influence of 
endocrine-stimulated growth factors (3). A 
significant increase in the expression of anti-
apoptotic factors is a key feature of this 
proliferative phase (4). In mid pregnancy, USM 
cells switch into a synthetic phase characterized 
by cellular hypertrophy, extracellular matrix 
remodelling and activation of apoptotic 
pathways (3). The changes that occur during this 
phase are under the influence of both mechanical 
stimuli and endocrine hormones such as 
progesterone (2). Towards parturition, the cells 
adopt a more contractile phenotype, 
characterized by an up-regulation in the 
expression of contraction-associated proteins 
(CAPs) (2). The phenotypic changes in this 
phase are modulated by mechanical stimuli and 
sex-related hormones such as progesterone and 
estrogen. The molecular mechanisms regulating 
the transition of the USM through these different 
stages are limited and investigation of these 
mechanisms is of great importance given the fact 
that preterm labour is still the leading cause of 
neonatal morbidity and mortality (5,6).  
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 USM contraction is mainly regulated by 
phosphorylation of the regulatory light chain of 
myosin (MLC20) by Ca
2+ 
/calmodulin-
dependent myosin light chain kinase (MLCK), 
whereas relaxation is promoted by 
dephosphorylation of MLC20 by myosin 
phosphatase (PP1M) (7,8). Both MLCK and 
PP1M are regulated by several accessory 
proteins and one such protein is smoothelin-like 
protein 1 (SMTNL1) (9). Mouse SMTNL1 is 
divided into two separate domains: a unique N-
terminal domain (amino acids 1-346) and a C-
terminal single, type-2 calponin-homology 
domain (CH) domain (amino acids 346-459) that 
is helix-rich and globular in structure essential 
for binding tropomysin (9,10). Physiological 
studies in smtnl1-/- mice indicate that the protein 
plays a key role in modulating the contractile 
activity of smooth and striated muscle and is 
involved in adaptation in response to exercise 
and pregnancy (11,12). We recently showed that 
during sexual development and pregnancy 
MYPT1 (the myosin targeting subunit of PP1M) 
is a signalling target of SMTNL1. Deletion of 
SMTNL1 results in more than 30-fold increase 
in the expression of MYPT1 in neonates, 
gradually declining during sexual development. 
A significant increase in the levels of MYPT1 
was also seen in pregnant smtnl1-/- mice (11). 
Our findings suggested that SMTNL1 may 
function as a transcriptional regulator of MYPT1 
expression in smooth and striated muscle 
altering their contractile properties. This putative 
role is supported by nuclear localization of 
SMTNL1 upon phosphorylation at S301 in 
response to cAMP/cGMP and by the presence of 
a number of regulatory transcription factor 
binding sites in the promoter region of Smtnl1 
(11,13). SMTNL1 also shows sex related 
differences in expression and function, in that 
male mice have a two-fold increase in levels 
compared with females and exercise-adapted 
muscle tissues from smtnl1-/- female mice 
respond differently to adrenergic agonists 
(11,12). 
 Progesterone acting through its receptor 
PR plays a key role in the establishment and 
maintenance of pregnancy, coordinating many of 
the adaptive responses observed in USM (14-
16). PR is a member of the steroid hormone 
family of nuclear receptors and functions as 
ligand-activated transcriptional factor to regulate 
the expression of genes through binding to the 
corresponding hormone response elements 
within the promoter regions of target genes 
(17,18). PR is expressed in target cells as two 
distinct isoforms: PR-A and PR-B, generated 
from a single gene through the use of two 
alternative promoters (19,20). In USM, although 
the precise molecular mechanisms are unknown, 
PR is thought to promote relaxation by 
speficially inhibiting expression of the oxytocin 
receptor (OXTr) and FP receptor, targeted by the 
contractile agonists oxytocin and PGF2α (21-
25). In the case of PGF2α, PR is also involved in 
inhibiting the expression of key enzymes 
involved in the metabolism of PGF2α such as 
cyclooxygense-2 (COX-2) and 15-hydroxy-PG-
dehydrogenase (PGDH) (26-29). Additionally, 
PR reduces the contractility and excitability of 
USM cells by inhibiting the expression of key 
gap junction proteins such as connexin 43 
(Cnx43) (30). Parturition in humans does not 
involve a drop in progesterone concentrations 
and thus, “functional progesterone withdrawal” 
in USM is achieved via an increase in the PR-
A:PR-B ratio (31,32). Concomitantly, this is 
associated with changes in the expression of 
both co-activators and repressors of PR 
transcriptional activity such as the co-activators 
SRC-2 and -3 and the co-repressors PSF 
(polypyrimidine tract-binding protein-associated 
splicing factor) and p54nrb (non-POU-domain-
containing, octamer binding protein) (33-36). 
Additionally, the miR-200 family and their 
targets, ZEB1 and ZEB2 are identified as unique 
progesterone/PR-mediated regulators of USM 
contractility during pregnancy (37). 
 In this study, we identify SMTNL1 as a 
previously unrecognized co-regulator of PR-B 
and in this capacity functions to regulate USM 
plasticity during pregnancy. We show that 
SMTNL1 directly and specifically binds PR-B 
and suppresses its transcriptional activity both in 
vivo and in vitro. We suggest that regulation of 
PR-B by SMTNL1 provides a molecular 
mechanism whereby PR-B is targeted to alter 
gene expression patterns within USM cells to 
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co-ordinately promote alterations in smooth 
muscle function during pregnancy. 
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Experimental Procedures 
Biochemicals  
SV40-hPR-B plasmid was provided by Ligand 
Pharmaceuticals. Flag-hPR-B was a gift from S 
Nordeen (University of Colorado health 
Sciences Center). Pgr 1294 antibody was a kind 
gift from Dean Edwards (Baylor College of 
Medicine).  
Mouse colony maintenance and pregnancy 
studies 
The smtnl1-/- mouse was created using standard 
protocols as described (Wooldridge et al, 2008). 
The transgenic mice were maintained by 
backcross breeding over 9 generations to a 129 
SvEv background. All mice were fed standard 
mouse chow (PMI5058 Picolab Mouse Diet 20, 
LabDiet) and water ad libitum.  Care of the mice 
used in the experiments met the standard set 
forth by the National Institutes of Health (NIH) 
guidelines for the care and use experimental 
animals. All procedures involving mice were 
approved by Duke University Animal Care and 
Use Committee.  In order to avoid shifts in the 
circadian rhythm and hence the estrous cycle, all 
animals were housed in identical polycarbonate 
cages and kept in environmentally controlled 
room (23+/-2 
o
C, 50+/-10 % relative humidity, 
frequent ventillation, and 12-12 hr light-dark 
cycle). For pregnancy studies 6-8 weeks matured 
female mice in estrus were selected by the 
apperanace of their vagina and also with lavage 
method of removing by gentle mechanical 
disruption following vaginal washes, stained 
with hematoxilin/eosin solution and analyzed by 
light microscopy. Female littermates caged 
together presented synchronized estrus in 98 % 
of cases. Females in estrus were mated with 
adult males overnight and then examined the 
following morning(s) for the presence of a 
vaginal plug. This was designated as day 0 of 
pregnancy. Mice were euthanized on selected 
day of pregnancy (day 7, 13, and 17), the day of 
giving birth (birth) and the second day of 
lactation.  
Study of reproductive fitness 
Smtnl1-/- colony breeding data was collected 
over a period of 1 ½ year from age-matched 
crosses generated between smtnl1+/+ x 
smtnl1+/+ and smtnl1-/-x smtnl1-/- mice 
(n=1651) given data on the litter size and the 
proportion of sexes. To gain data on embryonic 
lethality, time to pregnancy and the interval 
between pregnancy as the hallmarks of 
reproductive phenotype and the frequency of 
pregnancy smtnl1+/+ x smtnl1+/+ and smtnl1-/-x 
smtnl1-/- experimental breeder pairs (n=40 each) 
were used. The already proved fertile males and 
virgin females were in the age 6-8 w-old. Data 
are expressed as means and SEM.  
Cell culture 
HeLa, T47D and 293T cells were maintained in 
DMEM and HepG2 cells were maintained in 
MEM. When cells were treated with hormones, 
cells were cultured in phenol red-free medium 
containing 10% charcoal-stripped FBS plus the 
appropriate hormones for the indicated time 
periods. 
Mammalian two hybrid and luciferase assays 
Mammalian two hybrid assays were carried out 
in HepG2 cells. Cells were transfected Fugene 6 
reagent (Roche)with 1500 ng of 5xGal4-
luciferase reporter plasmid, 500 ng of VP16 or 
500 ng of nuclear receptor-VP16 fusion 
constructs (PR-A, PR-B (or PR-B 
deletion/mutant constructs), ERα, ERβ, AR, and 
GR), 500 ng of pM-Gal4DBD or pM-Gal4DBD-
SMTNL1 construct (or pM-SMTNL1 deletion 
constructs), 200 ng of cytomegalovirus β-
galactosidase (β-gal), and 300 ng of pBSIIKS 
plasmid for a total of 3µg of DNA per triplicate. 
Following a 24 h transfection, cells were treated 
with vehicle (ethanol) or with the corresponding 
receptors ligands as follows: 10nM of R5020 for 
PR-A and-B, 100 nM of 17ß-Estradiol for ERα 
and β, 100 nM of Dexamethasone for GR, 
100nM of R1881 for AR, or 100 nM of RU486 
and ZK98299. After an additional 24 h of 
incubation, the cells were harvested for 
luciferase and β-galactosidase assays. For 
analyzing the effects of 8-br-cAMP on PR-B 
transcriptional activity, HeLa cells were 
transfected with 10 ng of SV40-PR-B, 1500 ng 
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of MMTV-luciferase reporter plasmid, 200 ng of 
β-gal, and 1290 ng of pBSIIKS plasmid for a 
total of 3µg of DNA per well. After transfection, 
the cells were incubated with vehicle or 10 nM 
R5020 in the presence of 8-br-cAMP (10 nM-1 
mM) for 24 h and subsequently harvested for 
luciferase and β-gal assays. For analyzing the 
effects of SMTNL1 on PR-B transcriptional 
activity, reporter assays were carried out in 
HeLa cells. Cells were transiently transfected 
with 10 ng of SV40-PR-B, without (0 ng) or 
with increasing concentrations (75, 150 and 300 
ng) of pcDNA 3.1-SMTNL1 together with 1500 
ng of the MMTV-luciferase reporter plasmid and 
varying amounts of pBSIIKS plasmid for a total 
of 3µg of DNA per triplicate . The following 
day, cells were incubated with vehicle or 10 nM 
R5020 in the presence and/or of 100 µ 8-br-
cAMP for 24 h and subsequently harvested for 
luciferase and β-gal assays. Assays for 
endogenous PR-B transcription activity were 
carried out in T47D cells. pcDNA3.1-SMTNL1 
was transfected into T47D and the effects of 
increasing amounts of SMTNL1 (15 and 80 ng) 
on PR-B transcriptional activity ± R5020 and 8-
br-cAMP was measured. Data are presented as a 
normalized response, representing the absolute 
luciferase activity corrected for transfection 
efficiency by normalizing against the β-gal 
activity.  
Site-directed Mutagenesis 
All SMTNL1 mutants were created with the 
QuikChange mutagenesis kit (Stratagene) and 
completely sequenced for confirmation. Primers 
used in the mutagenesis experiments are listed in 
supplemental table IA. 
SMTNL1 silencing in T47D cells 
Double-stranded siRNA to knock down 
endogenous SMTNL1 protein levels and a 
scrambled-sequence were synthesized by 
Dharmacon Inc. (listed in supplemental table 
IC). The siRNAs were transfected into T47D 
cells using Dharmafect 1 transfection reagent 
(Dharmacon) according to the manufacturer’s 
protocol. After 48 h, the cells were treated with 
1 nM R5020 for another 12 h. Subsequently, 
cells were lysed and analyzed by Western blot 
analysis using anti-SMTNL1 and anti-PR 
antibodies.  
RNA isolation and RT-PCR 
RNeasy® Lipid Tissue Mini kit (Qiagen) was 
used to isolate total RNA from the uterus (n = 3) 
of WT and/or smtnl1-/- of pregnant and/or non-
pregnant mice. RNA (1µg) was reverse 
transcribed to cDNA using the iScript cDNA 
synthesis kit (Bio-Rad). PCR amplification was 
performed with iQ SYBR Green Supermix (Bio-
Rad) with 0.2 mM of each primer (see 
supplemental table IB for primer sequences). 
The 36B4 gene was used for the normalization 
of amplification.   
Microarray  
RNA was isolated from the uterus (n = 3) of WT 
and/or smtnl1-/- of pregnant (day 17) and/or 
non-pregnant mice. For microarray 
hybridizations, 100 ng of total RNA was 
amplified and labeled using the MessageAmp 
Premier Kit (Ambion). Equal amounts of labeled 
cRNA were hybridized to the Affymetrix Mouse 
Genome 430 2.0 microarray (Affymetrix) 
according to the manufacturer’s protocol. Partek 
Genomics Suite 6.4 (Partek Inc., St. Louis, MO) 
was used to perform data analysis. Robust multi-
chip analysis (RMA) normalization was done on 
the entire data set. Multi-way ANOVA and fold 
change were performed to select target genes 
that were differentially expressed between the 
different comparisons. Top differentially 
expressed genes were selected with p value of 
0.05 based on ANOVA test and fold change cut-
off of ≥ 2. Gene Ontology Enrichment analysis 
was performed with chi-square test and limited 
to functional groups with more than two genes. 
Hierarchical Clustering was performed based on 
Average Linkage with Pearson's Dissimilarity. 
GeneGo software was used for obtaining 
pathway maps and biological networks. All 
microarray experimental results are available at 
the Duke Microarray facility website 
(https://discovery.genome.duke.edu/express/reso
urces/2419).   
Immunoprecipitation, immunoblotting and 
mass spectrometry  
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Uterus (UT) samples of WT and smtnl1-/- mice 
in day 0 and 14 of pregnancy were homogenized 
as described previously (9). Samples were 
processed for immunoprecipitation (IP) and 
immunoblotting with specific antibodies against 
SMTNL1, PR and ERα. For IP experiments with 
293T cells, cells were transfected with Flag-
Smtnl1, Flag-PR-B, SV40-PR-B and pcDNA-
Smtnl1 as indicated. 48 h after transfection, 
media was replaced with fresh media ± 10 nm 
R5020 and incubated for 2 h. Subsequently, cells 
were processed as described previously (67). IPs 
were boiled for 10 min in SDS sample buffer, 
and proteins were resolved by 10% SDS-PAGE 
and visualized with silver staining.  For 
immunoblotting experiments, cells were lysed 
and processed for Western blotting with the 
corresponding antibodies as described 
previously (11). For mass spectrometry 
experiments, bands of interest from IP studies 
were in gel-digested with 0.6 μg of trypsin, and 
the tryptic peptides were subjected to MALDI 
TOF-TOF mass spectrometry.  
EIA assays 
Circulating progesterone and estradiol 
concentrations were determined by using ACE
TM
 
competitive enzyme immunoassays (Cayman 
Chemicals). Hormone concentrations were 
calculated in pg/ml. 
Variables and statistical analysis 
Litter size was the number of pups counted in 
each litter. Embryonic lethality was measured by 
searching uteri for dead embryos at the time of 
dissection either on day 7, 13, 17 of pregnancy 
or at birth and is reported as the mean number of 
dead embryos. Proportion of males was the 
percentage of male pups within each litter. Time 
to pregnancy was the number of days between 
the set-up of the breeding pair (with female in 
estrus) and the first observation of the plug 
(considered as day 0). Interval between 
pregnancies was the number of days between the 
first observation of the plug in the first 
pregnancy and the first observation of the plug 
in the second pregnancy. 
Normalized data were analyzed by t-tests (for 
two groups) or by general linear models (GLM, 
for >2 groups). Parametric statistical tests were 
used if the assumptions of such tests were met. 
We also log-transformed data for analyses. In 
GLMs, we tested all possible interaction terms 
and report here the final models obtained by 
excluding non-significant (p > 0.05) interactions. 
When any covariate or factor was significant in 
GLMs, we applied Tukey’s HSD procedure to 
test for pair wise differences in group means. 
Tests were conducted using the R statistical 
environment (R Development Core Team 2008) 
or SPSS 17.0 for Windows. 
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Results 
Deletion of SMTNL1 results in a poor 
reproductive phenotype  
Previous findings suggested an important role 
for SMTNL1in the regulation of smooth and 
striated muscle plasticity during pregnancy. In 
both vascular and USM SMTNL1 expression 
increased by more than 10 fold by day 13-17 of 
pregnancy compared to non-pregnant mice then 
declines steadily through parturition and the 
onset of lactation (11). To determine if loss of 
SMTNL1 function effects normal pregnancy we 
examined our smtnl1-/- mouse breeding 
database. After several thousand breedings we 
observed that litter sizes were smaller and 
embryonic lethality was higher in smtnl1-/- mice 
(table I). There was also a statistically significant 
increase in the proportion of male mice born 
relative to females (table I). Increased proportion 
of males to females within a population has been 
shown to be related to reduce overall fitness. 
Additionally, time to pregnancy was longer in 
smtnl1-/- mice and the intervals between 
pregnancies increased by 3-4 days (table I) 
although the latter difference was not 
statistically significant. These findings reveal 
that loss of SMTNL1 results in a phenotype of 
lower overall reproductive fitness as a 
physiological effect. 
 
Global gene expression profiles of uterine 
samples from smtnl1-/- and wild-type mice 
during pregnancy 
To more fully define SMTNL1 role in 
pregnancy, we performed microarray analysis 
using Affymetrix Mouse Genome 430 2.0 Array.  
Over 39,000 transcripts per single array were 
examined essentially encompassing the entire 
expressed mouse genome. Total uterine RNA 
was isolated from 3 different mice for each 
group; non-pregnant wild type (WN), wild type 
pregnant (WP), knock-out non-pregnant (KN), 
and knock-out pregnant (KP). Differentially 
expressed genes between the four comparisons 
are shown in a Venn diagram in figure 1A. 
Comparison 1 consisted of WT mice vs. smtnl1-
/- non-pregnant mice. This comparison identified 
31 genes differentially regulated between the 
two groups. Comparison 2 consisted of WT non-
pregnant mice and WT pregnant mice. This 
comparison identified 3276 that were 
differentially expressed. Comparison 3 consisted 
of knock out non-pregnant mice vs. knock out 
pregnant mice. This comparison identified 3766 
genes that were differentially expressed. Finally, 
comparison 4 consisted of analyzing WT 
pregnant mice vs. knock out pregnant. This 
comparison identified 128 genes (tables II and 
III) that were differentially expressed (Fig. 1B). 
Complete lists of genes for all four comparisons 
are available at the Duke Microarray facility 
website 
(https://discovery.genome.duke.edu/express/reso
urces/2419). Table II show a list of 81 genes 
which were up-regulated by more than 2-50 fold 
(n=3) in the WT pregnant mice vs. the smtnl1-/- 
pregnant ones and table III show a list of 47 
genes which were down-regulated by more than 
2-18 fold (n=3) in the WT pregnant mice when 
compared to the smtnl1-/- pregnant mice. 
Bioinformatic analysis of genes differentially 
expressed in this comparison identified the most 
significant pathways involved including: 
immune response (i.e., oncostatin M signaling 
via MAPK and histamine H1 receptor 
signalling), cell adhesion, cytoskeleton 
remodelling, proteolysis, histidine and proline 
metabolism, atherosclerosis, cAMP biosynthetic 
process and activation of protein kinase A, 
transport, plasminogen activation, steroid 
metabolic process and glucocorticoid receptor 
signalling, regulation of growth hormone 
receptor signaling pathway, and negative 
regulation of protein import into nucleus. 
Additionally, analysis of networks of 
transcriptional regulation identified sp1, c-myc, 
NF-kappaB1, stat3, stat5a, smad-2, -3, and -4, 
estrogen receptor α, and progesterone receptor as 
the major transcription factors involved in 
modulating gene expression in this comparison. 
Taken together, microarray analysis identified a 
number of signalling pathways involved in 
mediating the actions of SMTNL1 and strongly 
points to a role for the sex-related hormones 
estrogen and progesterone and their cognate 
receptors in SMTNL1 functions during 
pregnancy. 
 by guest, on August 24, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
8 
 
   Most notable in this comparison is the 
deregulation of the prolactin (PRL) family 
members in the smtnl1-/- pregnant mice. All 
members of this family with an observed 
expression on the array were found to be 
significantly down-regulated (3-18 fold) in the 
smtnl1-/- pregnant mice. The deregulation of 
prolactins in smtnl1-/- pregnant mice was 
confirmed by RT-PCR analysis. Accordingly, 
the mRNA for Prl3b1, Prl2a1, Prl7a1 and Prl2c2 
were all decreased markedly in knock out (KO-
P) pregnant mice when compared to their wild 
type counterparts (WT-P) (Fig. 2A). The 
significance of this finding will be elaborated on 
later in the context of the function of prolactins 
as mediators of pregnancy adaptations. 
Additionally, consistent with microarray results, 
RT-PCR analysis showed that the mRNA for 
Cyp26a1 and Slc13a1 were down-regulated in 
the KO-P mice (Fig. 2A). Uterine cyp26a1 
down-regulation in KO-P mice is intriguing 
given its role in the maintenance of pregnancy 
during the process of blastocycst implantation 
and the finding that cyp26a1 expression in the 
uterus is induced by steroid hormones (38-40). 
Additionally, we confirmed that the mRNA of a 
number of proteases (i.e., matrix 
metallopeptidases 13 and 3, arylsulfatase K, and 
ADAMTS-4 (a disintegrin and metalloproteinase 
with thrombospondin-like motifs)) which play 
an essential role in the ovulation process, 
through extracellular matrix remodelling, were 
all found to be down-regulated in the KO-P mice 
(41,42). We also confirmed that mRNA of Hal 
(histidine-ammonia lyase), the histidine-
degrading rate-limiting enzyme is up-regulated 
in KO-P mice when compared to their WT-P 
counterparts (Fig. 2B). The increase in Hal 
mRNA in smtnl1-/- pregnant mice is intriguing 
given the findings that the Hal gene is activated 
by glucocorticoids and glucagon via the PKA 
signalling pathway (43).  
SMTNL1 regulates the expression of ERα 
and PR-B in the primary genital tissues 
Microarray analysis support a role for SMTNL1 
is a key player in USM plasticity mediated 
through the sex-related hormones. To investigate 
this hypothesis further we examined the 
expression of SMTNL1 in the primary genital 
tissues selectively targeted by estrogen and 
progesterone. In non-pregnant uterus, SMTNL1 
is expressed within myometrial cells of the 
uterus as well as in the endometrial layer, and by 
day 13 of pregnancy expression is increased >10 
fold in both cell types (Fig. 3A and B). Non-
pregnant mammary gland shows a low level of 
SMTNL1 expression, with staining being 
confined to alveolus cells lining the lumens of 
intralobular duct systems, but by day 13 of 
pregnancy, the protein is induced 8-14 fold (Fig. 
3A and B). As observed previously the deletion 
of SMTNL1 does not appear to alter the ultra-
structure of any tissues, either non-pregnant or 
pregnant including uterus or mammary gland 
(12). Additionally, we observed a low level of 
SMTNL1 expression in the adrenal gland, but by 
day 13 of pregnancy, the protein is induced by 3-
4 fold (Fig. 3B). The adrenal cortex is devoted to 
the synthesis of glucocorticoids, 
mineralocorticoids and androgens and specific 
cell types within the cortex are associated with 
the synthesis of each of these steroid hormones. 
Examination of circulating progesterone (P) and 
estradiol (E) levels in smtnl1-/- mice showed 
SMTNL1 deletion produced a marginal 10-15% 
reduction in circulating E and P levels, 
suggesting a potential role in regulating steroid 
biosynthesis (Fig. 3C and D).  
 The findings that SMTNL1 is discretely 
expressed within reproductive tissues, coupled 
with the microarray analysis, supports links 
between the protein and steroid hormone action. 
To more fully understand this relationship, we 
first investigated the expression of both ER and 
PR in the uterus. Pregnancy induced expression 
of both ERα and PR-B in USM (Fig. 4A). The 
expression of both proteins  increased 3-4 fold in 
non-pregnant USM from smtnl1-/- mice and 8-9 
fold in USM from pregnant smtnl1-/- mice (Fig. 
4A). These data suggest a direct relationship 
between SMTNL1 expression levels and ER and 
PR expression. Next, we performed IP 
experiments from USM isolated from pregnant 
WT and smtnl1-/- mice. Figure 4B show that in 
both tissues SMTNL1 co-IP with PR-B but not 
ERα. As observed in Western blot experiments, 
IP of PR-B from USM extracts prepared from 
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smtnl1-/- mice showed a large induction of the 
protein. Similarly, although IP with ERα 
antibody confirmed the presence of ERα and 
PR-B in the IP as expected, Western analysis 
with anti-SMTNL1 antibodies indicated that 
SMTNL1 does not bind directly to ERα in vivo. 
Although our data do not support direct 
interactions of SMTNL1 with ERα, its increased 
expression observed after IP and Western 
analysis from smtnl1-/- mice may reflect either 
disruption of the ability of PR to suppress 
expression of ERα at the transcriptional level or 
that the increased expression of PR-B, by 
binding to ERα, stabilizes the protein. This 
notion is supported in studies by Beato et al 
demonstrating an interaction of PR-B with ERα 
in T47D cells (44,45). Although SMTNL1 does 
not bind ERα directly, any effects on ER 
expression are likely to indirectly affect 
SMTNL1 expression through the feedback 
mechanisms between PR and ER. Next, we 
performed quantitative RT-PCR experiments 
from USM isolated from both pregnant and non-
pregnant WT and smtnl1-/- mice to determine if 
the observed changes in PR-B could be seen at 
the transcriptional level. We chose a primer set 
directed at the sequence specific for PR-B. 
Figure 4C show that the mRNA levels of PR-B 
are up-regulated by more than 2 fold in pregnant 
smtnl1-/- mice when compared with WT 
pregnant mice. A slight, non-significant, 
increase in PR-B transcript was also observed in 
non-pregnant smtnl1-/- mice relative to the wild 
type non-pregnant mice (Fig. 4C). To further 
investigate the effect of SMTNL1 on the 
expression of PR-B in vivo, we developed 
several small interfering RNA (siRNA) 
constructs to knock down endogenous SMTNL1 
expression. For these experiments we chose the 
progestin-sensitive breast cancer cell line T47D 
due to the lack of a well-characterized USM cell 
lines expressing both proteins. Figure 4D shows 
R5020 induced the expression of both SMTNL1 
and PR-B by 5-10-fold. Treatment of the cells 
with SMTNL1 siRNAs effectively suppresses 
the expression of SMTNL1 regardless of R5020 
treatment. However, Western analysis of PR-B 
shows SMTNL1 siRNAs dramatically induce 
the expression of the receptor ~10 fold above 
that induced by R5020 alone (Fig. 4D). 
Collectively, these data provide direct evidence 
that SMTNL1 directly regulates expression of 
PR-B in vivo and that the effects of SMTNL1 
deletion on PR expression in smtnl1-/- mice are 
not the result of a non-specific adaptive response 
to chronic deletion of the gene in these animals. 
SMTNL1 binds PR in vivo and in vitro 
To determine the selectivity of SMTNL1 
towards the major steroid hormone receptors; 
progesterone receptor-A and -B, estrogen 
receptor-α and -β, androgen receptor (AR) and 
glucocorticoid receptor (GR) we carried out 
mammalian two-hybrid analysis. SMTNL1 was 
fused to the C-terminus of the GAL4 DNA 
binding domain in the pM vector and each of the 
steroid receptors was fused downstream of the 
Gal4 activation domain in the VP16 vector. 
Interaction between SMTNL1 and the steroid 
receptors was assessed by measuring the ability 
of the plasmids to activate transcription from a 
luciferase reporter in the presence or absence of 
the corresponding hormones. Figure 5A shows 
the remarkable degree of selectivity of SMTNL1 
for PR-B and -A over AR, GR, ERα and ERβ. 
Significantly, the interaction between SMTNL1 
and both isoforms of PR is hormone dependent. 
In the presence of R5020, reporter activity 
showed that SMTNL1 has much higher binding 
preference to the PR-B isoform when compared 
to PR-A.  In contrast, SMTNL1 did not show 
any significant interaction with ERα, ERβ in the 
presence or GR. A small, non-hormone 
dependent interaction was observed between 
SMTNL and AR. In comparative experiments, 
binding of SMTNL1 to PR-B and PR-A 
compares favourably with the well defined co-
activator steroid receptor co-activator-1 (SRC-1) 
NR box peptide (supplemental Fig. 1). However, 
unlike SMTNL1, SRC1-NR box does not 
discriminate between the steroid hormone 
receptors and binds to ERα as shown previously 
(46,47). Three proteins (SRC-1,-2, -3) have been 
identified in the p160 steroid hormone co-
activator family and each contains a short 
conserved NR interaction motif (NR box), which 
has the core sequence LXXLL (L = leucine and 
X = any amino acid) (48-50). SMTNL1 is 
therefore discriminated from all other known 
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steroid receptor-binding proteins in that it shows 
an exquisite degree of selectivity for PR A and B 
only. Additionally, SMTNL1 does not contain 
LXXLL motifs, suggesting that the protein 
interacts with PR at other sites and may have 
other functions. The finding that SMTNL1 only 
interacts with PR-B and A and not with either 
isoform of ER in 2-hybrid and Co-IP 
experiments suggests that the mechanisms of 
altered ER expression observed in vivo is likely 
to be mediated through PR via a feed back 
mechanism. Both estrogen and progesterone are 
known to regulate the expression of their 
corresponding receptors at the transcriptional 
level.  
 To further validate the observed in vivo 
interactions between SMTNL1 and PR-B, 293T 
cells were transfected with expression vectors 
for Flag-SMTNL1 and SV40-PR-B, and cell 
lysates were precipitated with flag beads. The 
Flag-SMTNL1 was able to co-IP SMTNL1 and 
PR-B (Fig. 5B).  Likewise, when cells were 
transfected with expression vectors for Flag-PR-
B and pCDNA-SMTNL1, the Flag beads were 
able to IP both Flag-PR-B and SMTNL1 (Fig. 
5C) and the presence of SMTNL1 was 
confirmed by Western blotting (Fig. 5C). Mass 
spectrometry studies confirmed the identity of 
the bands seen in the IP experiments (Fig. 5D). 
Additionally, endogenous SMTNL1 was found 
to co-IP with endogenous PR-B in T47D cell 
lysates as shown in figure 4E. Finally, co-
localization of SMTNL1 and PR-B was 
observed by immunofluorescent staining in 
T47D cells showing discrete nuclear localization 
for both proteins (Fig. 5F). 
Mapping the interaction sites between 
SMTNL1 and PR-B.  
Mammalian two-hybrid experiments were 
carried out to determine the regions(s) involved 
in interaction between SMTNL1 and PR-B. In 
the case of SMTNL1, aside from the CH 
domain, the protein has no defined domains and 
is quite unique with no sequence similarities to 
known proteins in the database. Our approach 
was to create small blocks of the protein and test 
them for their ability to bind PR-B. Accordingly, 
we created several truncated pieces of SMTNL1 
namely, amino acids 1-50, 1-60, 1-90, 1-150, 1-
200, 1-230, and 1-345. All constructs were fused 
to the C-terminus of the GAL4 DNA binding 
domain in the pM vector, sequenced and 
expression-validated. Figure 6A show that the 
first 60 amino acids of SMTNL1 are dispensable 
for PR-B binding whereas amino acids between 
60 and 90 are capable of restoring full binding 
capacity when compared to the full length 
protein. No significant increase in binding was 
observed when additional amino acids were used 
however, a significant increase in binding was 
observed with the 1-230 construct indicating that 
amino acids 200-230 of SMTNL1 are capable of 
interacting with PR-B (Fig. 6A).  Taken 
together, the results indicate that amino acids 60 
to 90 and amino acids 200 to 230 are required 
for SMTNL1 interaction with PR-B, with the 
later exhibiting a robust binding capacity when 
compared to the full length protein. Furthermore, 
the results indicate the CH domain, as expected, 
does not play a role in mediating the interaction 
between the two proteins.  
 Next, we carried out mammalian two-
hybrid experiments to determine regions of PR-
B necessary for its interaction with SMTNL1. 
The PR-B constructs employed in the assay 
include:  the N-terminal construct (amino acids 
1-555), amino acids 306-456, amino acids 456-
687, amino acids 680-933, the C587A 
transcriptional incompetent mutant, the mutant 
Pro construct, the G722C mutant, the AF2 
mutant (E907A/E911A), and the 1-922 construct 
(i.e., marks the end of the hormone binding 
domain). All constructs were fused downstream 
of the Gal4 activation domain in the VP16 
vector, sequenced and expression-validated. 
Figure 6B show that the C587A mutant 
abolished the interaction with SMTNL1 
completely. This construct of PR-B has a point 
mutation in the first zinc finger of the DNA 
binding domain and it disrupts the ability of PR 
to function as a transcription factor. When the 
AF2 mutant was tested, the level of the reporter 
activity generated was significantly reduced 
compared with that of the wild-type PR-B 
confirming the hormone dependence of the 
interaction between the two proteins (Fig. 6B). 
The 1-922 construct was still capable of binding 
 by guest, on August 24, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
11 
 
to SMTNL1 but the reporter level activity was 
reduced compared with that of the full length 
PR-B (Fig. 6B). The PR-B mPro mutant showed 
reduced binding when compared with that of the 
wild type protein (Fig. 6B). This construct has 
three essential prolines (P422, P423 and P426) 
changed to alanines which results in the loss of 
binding to the SH3 domains of signalling 
proteins. The G722C mutant (the 722 construct) 
was found to bind SMTNL1 with levels 
comparable to those of the wild type protein 
(Fig. 6B). This mutant generates a receptor that 
has lost detectable
 
RU486 binding, but retains 
wild-type binding affinity for progestin
 
agonists 
(51,52). The fact that SMTNL1 and PR-B is 
hormone-dependent prompted us to examine if 
the hormone binding domain of PR-B by itself is 
sufficient to bind SMTNL1. Figure 6B show that 
this is not the case, pointing to additional amino 
acids upstream that are required for mediating 
the interaction between the two proteins. Finally, 
as expected from the hormone-dependence of 
the interaction, constructs missing the ligand-
binding domain did not show any reporter 
activity (Fig. 6B). Comparative experiments 
with the co-activator SRC1-NR box are shown 
in supplemental figure 2.  Next, we used the 
mammalian two-hybrid system to examine the 
effects of anti-progestins (RU486 and ZK98299) 
on the interaction between SMTNL1 and PR-B. 
Treating the cells with anti-progestins resulted in 
significant reduction in the luciferase activity 
when compared to R5020 as shown in figure 6C. 
The significant reduction in the interaction of 
SMTNL1 with PR-B in the presence of anti-
progestins suggested that binding between the 
two proteins is a function of the conformational 
changes in PR-B and further validates the 
hormone-dependence of the interaction.   
SMTNL1 is a transcriptional co-regulator of 
PR-B function 
The significance of the interaction between 
SMTNL1 and PR-B was next investigated in the 
context of progesterone-responsive promoters 
and PKA mediated signalling. SMTNL1 is 
phosphorylated at S301in smooth muscle cells in 
response to 8Br-cAMP resulting in translocation 
of the protein to the nucleus, an effect blocked 
by S301A substitution (11). Activators of PKA 
are also known to affect the transcriptional 
activity of PR-B (53,54). Figure 7A shows 
treatment of HeLa cells, transfected with an 
expression vector for PR-B and MMTV-
luciferase reporter plasmid, with increasing 
amounts of 8Br-cAMP plus R5020 increases the 
transcriptional activity of PR-B in a dose 
dependent manner. This assay helped us 
determine the conditions for analyzing the effect 
of SMTNL1 on PR-B transcriptional activity at 
any given [8Br-cAMP]. Thus, HeLa cells were 
transfected with PR-B expression vector alone or 
with increasing amounts of SMTNL1 expression 
vector together with the MMTV-luciferase 
reporter in the presence and/or absence of R5020 
and 8Br-cAMP. Figure 7B show that SMTNL1 
inhibits PR-B tranasctivation in a dose-
dependent manner (i.e. 300 ng of SMTNL1 
causes more than 50% reduction in 
transcriptional activity). This effect correlates 
precisely with 8Br-cAMP concentrations 
(10µM) required to promote nuclear 
translocation of SMTNL1through S301 
phosphorylation (11). Increasing amounts of 
transfected SMTNL1 was also found to 
progressively repress endogenous PR-B activity 
by 20-30% in T47D cells (Fig. 7C). Taken 
together, these findings suggest that SMTNL1 
functions as a repressor of the transcriptional 
activity of PR in vivo. 
 As discussed earlier, progesterone 
promotes USM relaxation during pregnancy by 
repressing the expression of specific genes 
encoding CAPs (55). Specifically, PR inhibits 
the expression of key CAPs including OXTR, 
Cnx-43, and COX-2 (21-29)  Therefore, if 
SMTNL1 represses PR, one might predict loss 
of this function in smtnl1-/- mice would lead to 
altered expression of PR regulated genes. Figure 
7D shows this is indeed the case. Quantitative 
RT-PCR studies show that mRNA for OXTR, 
Cnx-43 and COX-2 were all decreased markedly 
in the KO-P mice compared to their WT-P 
counterparts (Fig. 7D). These findings support 
SMTNL1 as a novel co-regulator of PR-B 
transcriptional activity in USM.  
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Discussion 
In the present study we show that SMTNL1 
plays a key role in pregnancy to promote 
adaptive responses in USM and that this process 
is mediated through interactions of SMTNL1 
with the progesterone receptor PR-B. Both in 
vitro and in vivo SMTNL1 specifically binds to 
the progesterone receptor and not other steroid 
hormone receptors, discriminating the protein 
from all other known co-regulators of this class 
of nuclear receptors. Both SMTNL1 and PR 
exhibit co-regulation of expression during 
normal pregnancy and there is a significant 
increase in PR expression at the protein level in 
smtnl1-/- mice in both reproductive and non-
reproductive tissues. Additionally PR expression 
is significantly induced in response to RNA 
interference of SMTNL1 in progesterone 
sensitive cell lines. These observations therefore 
show a direct role for SMTNL1 in regulating the 
expression of PR itself. Additionally, 
transcriptional reporter assays and global gene 
expression analysis suggest a mechanism of 
action in which SMTNL1 functions as a co-
regulator of PR-B transcriptional activity to 
regulate gene expression in reproductive tissues 
underling the physiological relationship between 
the two proteins. Consistent with this role, 
quantitative RT PCR studies of several known 
contractile associated proteins (CAPs) regulated 
by PR-B were greatly suppressed in USM from 
smtnl1-/- mice. Global gene analysis also 
showed that a primary target of SMTNL1 are 
prolactins, a well defined group of genes 
governing both pregnancy and lactation that are 
also involved in progesterone production in the 
late stages of pregnancy. All prolactin genes 
were greatly suppressed in global gene 
expression of tissues from smtnl1-/- mice and 
these findings were also confirmed in RT-PCR 
studies. Clearly our findings define SMTNL1 as 
a homeostatic regulator of PR function during 
pregnancy. Figure 8 outlines three potential 
modes of action that are currently under 
investigation.   
 Our hypothesis that SMTNL1 functions 
as a co-regulator of PR-B stems from several 
lines of evidence. First, IP and Western assays of 
PR-B from smtnl1-/- pregnant mice USM 
extracts showed a significant increase in the 
induction of the protein in comparison to the WT 
extracts. This increase is also evident at the 
transcript level; quantitative RT-PCR data 
showed a 2-3-fold up-regulation of PR-B mRNA 
levels in pregnant smtnl1-/- mice when 
compared with their WT pregnant litter mates. 
Second, in reporter assays, SMTNL1 was found 
to inhibit PR-B transcriptional activation in a 
dose-dependent manner and the effect was 
shown to be independent of cell and promoter 
context, ruling out the involvement of 
transcriptional interference. Finally, the 
necessity for a functional DBD and AF2 for 
SMTNL1 binding puts the protein at the core of 
PR transactivation given the fact the primary 
role of the DBD is to bind to specific DNA 
target sequences within the promoter of 
responsive genes, and the established functions 
of AF2 as a mediator of hormone-dependent 
transcriptional activation. It is intriguing to think 
that the reduction of PR-B transcription by 
SMTNL1 is due to the formation of an 
inhibitory complex that is either unable to bind 
DNA or is incapable of binding to the 
transcription machinery. Future studies will test 
this hypothesis by electrophoretic mobility shift 
and CHIP assays. Additionally, SMTNL1 
phosphorylation could play a role in mediating 
its effects on PR-B since the S301A SMTNL1to 
alanine blocks entry into the nucleus (11). 
Furthermore, reduction of PR-B transcriptional 
activity was only detected when cells were 
treated with PKA activators (53,54). If SMTNL1 
acts as a transcriptional co-regulator of PR in 
vivo inhibiting its function, phosphorylation of 
one or more sites may be similar to deleting the 
protein as observed in smtnl1-/- female mice. 
Such a mechanism of action may imply that the 
default function for SMTNL1 in non-pregnant 
animals is to repress PR function from 
promoting pregnancy-like adaptive responses in 
USM. The observed repression of key CAPs in 
smtnl1-/- pregnant mice is consistent with such 
role. The molecular mechanism(s) by which 
SMTNL1 deletion promotes an increase in the 
transcriptional activity of PR-B in vivo is 
currently under further investigation.  
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 In specific pathway analysis related to 
progesterone and pregnancy, most notable was 
the effect of SMTNL1 deletion on the PRL 
family members. All members of this family 
with observed expression on the array were 
found to be down-regulated in the smtnl1-/- 
pregnant mice. In rodents, PRLs are a large 
family of proteins that share extensive structural 
and functional homology and are synthesized in 
all reproductive tissues in a temporal manner 
(56,57). The PRL family are associated with an 
array of functions, however, their involvement in 
reproduction has received the most attention 
(58). Studies of PRL-/- and PLR-R-/- mice 
results in complete infertility in females due to 
failure of implantation (59,60). These mice show 
a lack of functional corpus luteum (CL) and 
thus, were unable to produce progesterone. The 
CL plays a central role in the maintenance of 
pregnancy through regulating the production of 
progesterone (61). In rodents, the functions of 
the CL are sustained throughout pregnancy by 
coordinating the secretion of PRLs (56,62). The 
deregulation of the PRLs in smtnl1-/- pregnant 
mice is very interesting given our observations 
that deletion of SMTNL1 is associated with a 
slight reduction in the levels of progesterone in 
late pregnancy. Taken together, our results 
highlight a previously unrecognized role for 
SMTNL1 as an activator of the expression 
and/or release of a subset of the PRL family 
members during late pregnancy. Future studies 
will focus on elucidating the mechanism(s) of 
SMTNL1 activation of PRLs and their effect on 
progesterone production using a culture system 
of luteal cells from WT and smtnl1-/- pregnant 
mice.   
  Finally, analysis of smtnl1-/- mouse 
breeding data base showed that the loss of 
SMTNL1 results in smaller litter sizes and 
higher embryonic lethality. Additionally, we 
observed that time to pregnancy was longer in 
smtnl1-/- mice. Collectively, our data indicate 
that loss of SMTNL1 results in a phenotype of 
lower overall reproductive fitness as a 
physiological effect. These phenotypic effects 
are distinct from those observed in PR null mice. 
PR-A null mice developed signs of uterine 
dysplasia and abnormal ovaries resulting in 
female infertility, whereas PR-B null mice did 
not show any uterine abnormalities but exhibited 
signs of mammary glands malformations (63-
66). The differences between smtnl1-/- mice and 
the severity of the PR null phenotype further 
support the hypothesis that SMTNL1 functions 
to affect a subset of PR genes.  
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 Figure legends 
Table 1. Smtnl1 deletion results in a poor reproductive phenotype. Smtnl1-/- colony breeding data 
was collected over a period of 1 ½ year from age-matched crosses generated between smtnl1+/+ x 
smtnl1+/+ and smtnl-/- x smtnl1-/- mice (n=1651). Data on embryonic lethality, time to pregnancy and 
the interval between pregnancy as the hallmarks of reproductive phenotype and the frequency of 
pregnancy were collected. Data are expressed as means and ± SEM.  
Table II.  Genes up-regulated in wild type pregnant (WP) vs. smtnl1-/- pregnant (KP) mice. 
Table III.  Genes down-regulated in wild type pregnant (WP) vs. smtnl1-/- pregnant (KP) mice. 
Figure 1. Venn diagram demonstrating the relationship between genes differentially regulated in 
the different comparisons and hierarchical clustering analysis of the wild type pregnant (WP) vs. 
knock-out pregnant (KP) mice. (A) Venn diagram; the numbers within the intersections of the circles 
indicate the common genes between the different groups. The numbers outside the circles indicate the 
number of genes differentially-regulated between the two groups as indicated. (B) Hierarchical clustering 
analysis of the differentially expressed genes in the WP vs. KP comparison. The color code for the signal 
strength is shown in the box at the bottom; induced genes are indicated by red and repressed genes are 
indicated by blue.  
Figure 2. Quantitative RT-PCR validation of microarray data. QRT-PCR analysis of Prl3b1, Prl2a1, 
Prl7a1, Prl2c2, Cyp26a1, Slc13a1 and (D) Hal in wild type pregnant (WT-P) and smtnl1-/- pregnant (KO-
P) mouse uteri. The results represent the mean ± SEM, n= 3 RNA sets. 
Figure 3. Pregnancy regulates SMTNL1 expression in the primary genital tissues. (A) IH images of 
SMTNL1 localization in uterus and mammary gland from control and pregnant WT and smtnl1-/- mice. 
Scale bars represent 20 μm. m: myometrium, e: endometrium, g: endometrial glands in tunica propria of 
uterine mucosa (B) Pregnancy induces significant expression of SMTNL1 relative to control (non-
pregnant) in USM, mammary gland and adrenal gland. Inserts below show representative Western blots. 
Data shown is from day 0 and day 14 of pregnancy. (C and D) Circulating hormone concentrations of 
smtnl1+/+ and smtnl1-/- mice during pregnancy.  The circulating progesterone (E) and estriol (F) 
concentration is lower in smtnl11-/- mice in pregnancy. Means ± SEM, n = 4-6 animals, GLM with 
Tukey-test, different letters indicate significant differences (p < 0.05).  
Figure 4. SMTNL1 regulates the expression of ERα and PR-B in USM. (A) Pregnancy and SMTNL1 
deletion promotes a higher expression of PR-B and ERα in USM. Insert below show representative 
Western blots. Data shown is from day 0 (con.) and day 14 of pregnancy (preg.). (B) SMTNL1, PR-B and 
ERα co-IP studies from uterine extracts of WT-P and smtnl1-/- P. (C) PR-B mRNA levels are up-
regulated in the pregnant uteri of smtnl1-/- compared to WT mice. RT-PCR results of PR-B mRNA levels 
in USM from aged matched pregnant (preg.) and non pregnant (con.) WT and smtnl-/- mice, n = 3 ± 
SEM. (D) T47D cells were transfected with either siRNA control or siRNA directed against SMTNL1. 
Subsequently, cells were treated with the synthetic progestin R5020 (+) (1 nM) or ethanol (-) for 12 
hours, lysed and analyzed by Western blot analysis using antibodies against SMTNL1 and PR-B.   
Figure 5. SMTNL1 binds PR in vivo and in vitro. (A) HepG2 cells were transfected with the indicated 
constructs. After 24 h, cells were treated with different receptors ligands as indicated and subsequently 
harvested for luciferase and β-gal assays. (B) 293T cells were transfected with the indicated expression 
vectors. After 48 h, the culture media was replaced ± 10 nM R5020 for 2 hours. Lysates were IP using 
Flag beads and processed for SDS-PAGE and silver stain. (C) IPs were subjected to the same treatment as 
in (B) and then probed with an antibody against SMTNL1. (D) Designated bands (SMTNL1 and PR-B) 
were excised and processed for mass spectrometry. Peptide sequences and their position in each protein 
are shown. (E) T47D cells were lysed and lysates were incubated with SMTNL1 or PR antibodies, and IP 
with protein A-Sepharose. IPs were Western blotted with  SMTNL1 and PR antibodies. (F) Nuclear co-
localization (merge, white) of endogenous SMTNL1 (green) and PR (red) in T47D cells. Scale bars = 
10µm. 
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Figure 6. Identification of interaction sites within SMTNL1 and PR-B.  (A) HepG2 cells were 
transfected with the indicated SMTNL1 deletion constructs together with PR-B. (B) HepG2 cells were 
transfected with the indicated PR-B deletion constructs and mutants together with SMTNL1. In both (A) 
and (B), 24 h after, the cells were incubated with vehicle or 10 nM R5020 for 24 h then harvested for 
luciferase and β-gal assays. (C) Effects of anti-progestins on SMTNL1-PR-B interaction. After 
transfection, the cells were incubated with (vehicle) or 10 nM R5020, 100nM RU486 and 100nM 
ZK98299 for 24 h and harvested for luciferase and β-gal assays. 
Figure 7. SMTNL1 regulates PR-B expression at the transcriptional level. (A) Effect of cAMP on the 
transcriptional activity of PR-B.  HeLa cells were transfected with an expression vector for PR-B and an 
MMTV-luciferase reporter plasmid. After transfection, cells were incubated with vehicle or 10 nM R5020 
in the presence of 8Br-cAMP (10 nM-1mM) for 24 h and harvested for luciferase and β-gal assays. (B) 
Effect of SMTNL1 on PR-B transcriptional activity. HeLa cells were transfected with PR-B expression 
vector without (0 ng) or with increasing concentrations (75, 150 and 300 ng) of SMTNL1 expression 
vector together with the MMTV-luciferase reporter plasmid. The following day, cells were incubated with 
vehicle or 10 nM R5020 for 24 hours and subsequently harvested for luciferase and β-gal assays. (C) 
SMTNL1 was transfected into T47D and the effects of increasing amounts of SMTNL1 (15 and 80 ng) on 
PR-B transcriptional activity ± R5020 and ± 10 µm 8Br cAMP was measured. (D) RT-PCR analysis of 
OXTR, Cnx-43 and Cox-2 in wild type pregnant (WT-P) and smtnl1-/- pregnant (KO-P) mouse uteri, n= 
3 RNA sets ± SEM. 
Figure 8. Mechanisms by which SMTNL1 regulates PR-B to co-ordinately promote USM 
adaptations in pregnancy. Schematics A and B show regulation of expression of SMTNL1, PR and ER 
are regulated via two possible homeostatic feedback mechanisms. In (A) the synthesis of PR is controlled 
by estrogen acting through ER. Progesterone (P4) abrogates estrogen induction by down-regulating ER 
protein concentration, decreasing circulating estrogen levels and antagonizing ER action at the molecular 
level. ER may also have a direct effect on SMTNL1 transcription, a hypothesis supported by the presence 
of ER binding sites in the promoter region of smtnl1. In (B) SMTNL1 directly and specifically binds PR-
B, in a hormone-dependant manner, and suppresses its transcriptional activity. A likely means by which 
SMTNL1 regulates PR-B is via PKA-mediated phosphorylation. Both proteins have multiple in vivo 
phosphorylation sites and, at least one of these sites, S301 has the potential to affect SMTNL1 entry into 
the nucleus. Therefore, by phosphorylating SMTNL1, it may be possible to activate or inhibit its effects 
on PR function. In (C) SMTNL1 also functions as an activator of the expression and/or release of a subset 
of the PRL family members (i.e., placental lactogens) which are involved in progesterone production in 
late pregnancy and thus regulating PR transcriptional activity. Taken together, we suggest that regulation 
of PR by SMTNL1 provides a molecular mechanism whereby PR is directed to alter gene expression 
patterns within USM (i.e. CAPs) to co-ordinately promote alterations in USM function during pregnancy. 
┴ (inhibition) → (gene transcription). 
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Table 1. 
 smtnl1+/+ smtnl1-/-  
Litter size 
 
7.14±1.47 4.23±1.25***  t = 5.961,n=70;  df = 30, 
 p < 0.001 
Embryonic 
lethality 
0.05 ± 0.22 0.4 ± 0.68* t23=2.185, p=0.039 
Proportion 
of males 
44% ± 19.4% 57% ± 21.8% t394 = 1.768, df = 30, p = 0.087 
Time to 
pregnancy 
2.8 ± 1.37 4.6 ± 2.23* t38 = 3.156, p = 0.003 
Interval 
between 
pregnancies 
23.6 ± 2.65 27.5 ± 6.22* t16 = 1.827, p = 0.086 
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Table II. 
Probeset ID Gene Symbol Fold-Change p-value 
1452426_x_at --- 50.3404 0.0118484 
1415835_at Prl3b1 17.5723 0.000565294 
1427760_s_at Prl2c2 /// Prl2c3 /// Prl2c4 12.0257 7.87E-05 
1436717_x_at Hbb-y 10.5434 0.0402453 
1448532_at Prl8a9 9.53893 0.0063006 
1436823_x_at Hbb-y 9.23758 0.0497143 
1457446_at Opcml 6.89362 0.00252789 
1419430_at Cyp26a1 5.71716 0.0325249 
1431379_a_at Slc13a1 5.55238 0.0271946 
1435330_at Pyhin1 5.16049 2.88E-06 
1417256_at Mmp13 4.82501 3.77E-05 
1460480_at Erv3 4.79078 0.0198751 
1416444_at Elovl2 4.56532 0.0109421 
1424959_at Anxa13 4.54885 0.0185272 
1422640_at Pcdhb9 4.50123 0.00292992 
1429835_at 2310033E01Rik 4.46294 0.00207603 
1456211_at Nlrp10 4.26845 0.00389898 
1449529_s_at Prl7a1 4.24167 4.67E-07 
1419764_at Chi3l3 3.95692 0.00726454 
1450621_a_at Hbb-y 3.94281 0.0248618 
1449227_at Ch25h 3.91637 0.00256177 
1448608_at Prl8a2 3.90766 0.0202838 
1419700_a_at Prom1 3.74858 0.0467971 
1435212_at P2rx2 3.52183 0.0191051 
1453109_at Arsk 3.46635 0.00739499 
1422240_s_at Sprr2h 3.34212 0.048739 
1460670_at Riok3 3.32078 0.00880283 
1455965_at Adamts4 3.30621 0.000183407 
1416523_at Rnase1 3.2957 0.0272699 
1443109_at --- 3.20581 0.000563566 
1443122_at --- 3.11984 0.0268743 
1444198_at --- 3.11473 0.000703871 
1459183_at --- 3.01381 0.00259112 
1455963_at 6332401O19Rik 3.0044 0.00312948 
1449211_at Bpnt1 3.00332 9.99E-05 
1437667_a_at Bach2 2.99958 0.000357257 
1434171_at C330011K17Rik 2.96357 0.0282958 
1446130_at --- 2.94778 6.58E-06 
1435532_at LOC100048362 2.90419 0.0176285 
1420282_s_at Prss29 2.88675 0.000879869 
1439475_at Zfp429 2.87303 0.00605254 
1450364_a_at Havcr1 2.85818 0.0352559 
1450802_at Prss28 2.84496 2.72E-05 
1435612_at Opcml 2.76545 0.00503496 
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1449992_at Prss29 2.7388 0.00216172 
1444262_at 1110017F19Rik 2.72515 0.0069375 
1447096_at --- 2.70101 0.0150339 
1449032_at Prl2a1 2.63682 0.0171069 
1448650_a_at Pole 2.59374 0.0247163 
1429053_at 1110012J17Rik 2.57509 0.00376077 
1420566_at --- 2.48943 0.029121 
1429691_at Ptprg 2.48249 0.00238895 
1448025_at Sirpb1 2.46555 0.00830697 
1456688_at --- 2.41953 0.00133759 
1418945_at Mmp3 2.41295 0.0426652 
1429982_at 4933426K21Rik 2.4034 0.00943209 
1425951_a_at Clec4n 2.38158 0.00402976 
1435533_s_at 4933426K21Rik  2.37328 0.0255649 
1458659_at Plac9 2.37271 0.0287112 
1447231_at --- 2.36516 0.0234413 
1425451_s_at Chi3l3 /// Chi3l4 2.34073 0.0443562 
1455208_at Pex19 2.30199 0.00568377 
1424502_at Oit1 2.28795 0.0242847 
1418429_at Kif5b 2.2702 0.000310519 
1424843_a_at Gas5 2.26929 0.0011463 
1449475_at Atp12a 2.26072 0.0445511 
1418764_a_at Bpnt1 2.25707 0.00255535 
1459661_at Dcdc2a 2.24712 0.0225015 
1418156_at Kcne4 2.23922 0.001954 
1443939_at OTTMUSG00000008561 2.22234 0.0276062 
1417280_at Slc17a1 2.21315 0.00660674 
1419627_s_at Clec4n 2.16441 0.00979708 
1419405_at Nmb 2.16288 0.00802374 
1447202_at 1200009F10Rik 2.13809 0.000141127 
1450291_s_at Ms4a4c 2.12471 0.0362122 
1420604_at Hesx1 2.1143 0.000794586 
1452590_a_at Plac9 2.10211 0.0306398 
1446141_at --- 2.09829 0.0202272 
1449388_at Thbs4 2.09591 0.0033629 
1437636_at LOC623121 2.04626 0.000233143 
1436222_at Gas5 2.01476 0.00126799 
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Table III. 
Probeset ID Gene Symbol Fold-Change p-value 
1432216_s_at Mpp7 -2.00481 0.00230603 
1428891_at 9130213B05Rik -2.00806 0.02324 
1449394_at Slco1b2 -2.01627 0.0272746 
1427451_a_at BC018473 -2.07375 0.0153867 
1451625_a_at C8g -2.0821 0.0437489 
1427001_s_at Hnf4a -2.08448 0.0224681 
1445824_at Zfp458 -2.11182 0.00204125 
1417920_at Amn -2.11539 0.0438993 
1442255_at --- -2.11813 0.0241017 
1450839_at D0H4S114 -2.15096 0.0101531 
1448837_at Vil1 -2.16171 0.0234569 
1439109_at Ccdc68 -2.17935 0.0153504 
1459733_at --- -2.18599 0.000581386 
1451610_at Cxcl17 -2.1862 0.0493382 
1457435_x_at Myom2 -2.20231 0.0138509 
1419670_at Ftcd -2.23909 0.00127039 
1439117_at Clmn -2.25626 0.0125216 
1425749_at Stxbp6 -2.27681 0.0413114 
1417600_at Slc15a2 -2.29336 0.0182215 
1438699_at Srd5a1 -2.30676 0.0383523 
1431101_a_at Srd5a1 -2.32013 0.0246874 
1457025_at 4833413O15Rik -2.36177 0.01158 
1424072_at 2010107G23Rik -2.38241 0.000154301 
1422846_at Rbp2 -2.4153 0.0449952 
1433845_x_at Dusp9 -2.47057 0.00662899 
1456495_s_at Osbpl6 -2.48547 0.0397768 
1456321_at Npal1 -2.52829 0.0261785 
1429166_s_at Clmn -2.52865 0.00630892 
1453444_at 5730437C12Rik -2.58443 0.0125215 
1416677_at Apoh -2.65625 0.0337181 
1417462_at Cap1 -2.7564 0.0142922 
1457483_at --- -2.7689 0.00187144 
1417461_at Cap1 -2.83218 0.0082928 
1452707_at Klhl30 -3.00085 0.027121 
1421445_at Slc26a3 -3.29019 0.008087 
1416980_at Mettl7b -3.44204 0.00469039 
1449088_at Fbp2 -3.68493 0.0415826 
1419063_at Ugt8a -3.98828 0.0118296 
1451788_at F11 -4.324 0.00883293 
1428301_at LOC671957 -4.41548 0.00540577 
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1429467_s_at Slc26a3 -4.41934 0.0103699 
1459253_at Arrdc3 -4.77537 0.0106758 
1452731_x_at B930046C15Rik  -5.40964 0.00252296 
1427798_x_at --- -5.44483 0.0171833 
1427797_s_at --- -7.61701 0.0375428 
1439055_at OTTMUSG00000001305 -9.19592 5.53E-05 
1418645_at Hal -18.0734 7.10E-06 
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